RadNetの空売り状況は、投資家がRadNetの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

RadNet (NASDAQ:RDNT) 株価情報, 空売り情報

RadNet

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

RadNet Inc

Truist Securities analyst David Macdonald reiterates RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and lowers the price target from $94 to $88.

News

Price Target

Reiteration

Analyst Ratings

RDNT

Truist Securities Reiterates Buy on RadNet, Lowers Price Target to $88

5 analysts have shared their evaluations of RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $86.6, a high estimate of $100.00, and a low estimate of $74.00. This upward trend is evident, with the current average reflecting a 1.64% increase from the previous average price target of $85.20.
<img src="https://www.benzinga.com/files/images/story/2025/1737554416_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RadNet. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of RadNet's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into RadNet's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>All You Need to Know About RadNet</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>A Deep Dive into RadNet's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining RadNet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.72% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: RadNet's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RadNet's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.36%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): RadNet's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.94.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down RadNet: 5 Analysts Share Their Views

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Overweight and lowers the price target from $85 to $74.

Barclays Maintains Overweight on RadNet, Lowers Price Target to $74

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</h3>
<ul>
<li>On Jan. 17, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company' stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/VKTX">52-week low of $20.83</a>.</li>
<li>RSI Value: 28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">latest VKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png" alt="" class="wp-image-744179" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-768x707.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company's stock fell around 11% over the past five days and <a href="https://www.benzinga.com/quote/RDNT">has a 52-week low</a> of $35.16.</li>
<li>RSI Value: 25.2</li>
<li>RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">trend in RDNT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png" alt="" class="wp-image-744183" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-768x704.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)</h3>
<ul>
<li>On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera's position in B cell modulation. The company's stock fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VERA">low of $15.46.</a></li>
<li>RSI Value: 27.2</li>
<li>VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">VERA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png" alt="" class="wp-image-744188" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-768x719.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

VERA

VKTX

Top 3 Health Care Stocks That Could Blast Off This Quarter

WIIM

RadNet shares are trading lower after Jefferies cut its price target on the stock from $100 to $80.

Jefferies analyst Brian Tanquilut maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and lowers the price target from $100 to $80.

Jefferies Maintains Buy on RadNet, Lowers Price Target to $80

Jefferies analyst Brian Tanquilut maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $82 to $100.

Jefferies Maintains Buy on RadNet, Raises Price Target to $100

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Overweight and raises the price target from $79 to $85.

Barclays Maintains Overweight on RadNet, Raises Price Target to $85

<ul>
<li>Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology&#x2122; to improve patient experience and operational efficiency in ultrasound.</li>
<li>The collaboration aims to facilitate remote operations, collaboration, and enhanced interpretation capabilities for increased diagnostic accuracy and consistency by combining Siemens Healthineers' Acuson Sequoia with RadNet's DeepHealth SmartSonograp</li>
</ul>

Reported Earlier, Siemens Healthineers And RadNet's DeepHealth Join Forces To Elevate Ultrasound Workflows With AI-powered SmartSonography

4 analysts have expressed a variety of opinions on RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $83.25, a high estimate of $94.00, and a low estimate of $79.00. Witnessing a positive shift, the current average has risen by 18.09% from the previous average price target of $70.50.
<img src="https://www.benzinga.com/files/images/story/2024/1732906829_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to RadNet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of RadNet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into RadNet's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>Get to Know RadNet Better</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Breaking Down RadNet's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: RadNet displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.72%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: RadNet's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.36%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): RadNet's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: RadNet's debt-to-equity ratio is below the industry average. With a ratio of 1.94, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For RadNet

Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $80 to $94.

Truist Securities Maintains Buy on RadNet, Raises Price Target to $94

RadNet's DeepHealth Subsidiary Expands FDA Clearance For SmartMammo Solution; Clearance Enables  RadNet's DeepHealth and GE HealthCare Collaboration To Bring Together The SmartMammo And Senographe Pristina Solutions For Breast Cancer Diagnosis

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock rose 175.6% to $0.19 during Monday's pre-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 27.07% to $2.3. The company's market cap stands at $4.2 million. As per the press release, Q3 earnings came out today. </li>
<li>RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) shares increased by 22.7% to $89.0. The market value of their outstanding shares is at $6.5 billion. The company's, Q3 earnings came out today. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 21.95% to $1.0. The company's market cap stands at $3.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares increased by 21.28% to $4.33. The market value of their outstanding shares is at $171.6 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares increased by 19.37% to $4.93. The company's market cap stands at $1.7 billion. As per the news, the Q3 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares declined by 48.1% to $1.5 during Monday's pre-market session. The company's market cap stands at $52.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares decreased by 17.3% to $1.1. The company's market cap stands at $26.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 15.55% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 13.73% to $3.71. The company's market cap stands at $4.9 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock decreased by 10.68% to $178.2. The market value of their outstanding shares is at $314.6 billion. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares fell 8.46% to $2.6. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABBV

CERO

DWTX

FRES

NUWE

RAPT

REVB

SNES

TIVC

VIGL

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.
Shares of MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) rose sharply during Monday's session amid <a href="https://www.benzinga.com/quote/MARA">strength in Bitcoin</a>.
Prices for Bitcoin surged above the $82,000 level on Monday.
MARA Holdings shares jumped 17.3% to $22.59 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) shares surged 40.8% to $1.7750 after Bitcoin rose above $82,000</li>
<li>RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) surged 24.8% to $90.53 after the company reported better-than-expected third-quarter financial results.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares jumped 23.2% to $5.29 amid strength in Bitcoin prices.</li>
<li>Cango Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) gained 19.7% to $4.0700.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares surged 19.1% to $10.67.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) rose 18% to $33.56.</li>
<li>Nano-X Imaging Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) rose 16.8% to $7.12.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 16.5% to $22.81 after Bitcoin rose above $82,000.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) rose 16% to $14.84 after Bitcoin rose above $82,000.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 14.2% to $26.72.</li>
<li>Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) gained 13.5% to $12.47.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) jumped 13.3% to $306.99 amid strength in Bitcoin.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) gained 11.7% to $60.50. The stock may be moving in response to AbbVie after the company announced its two Phase 2 EMPOWER trials did not meet its primary endpoint.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) rose 10.1% to $7.82.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) gained 8.5% to $130.47.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) climbed 8.2% to $50.31.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 8.2% to $33.03 after Morgan Stanley maintained an Equal-Weight rating on the stock and raised its price target from $22 to $24.</li>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) rose 6.6% to $340.70 after the company confirmed it is not pursuing a combination with Humana.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/41874548/top-4-health-care-stocks-that-may-plunge-this-quarter">Top 4 Health Care Stocks That May Plunge This Quarter</a></li>
</ul>

Intraday Update

AFRM

BTBT

BTDR

CANG

COIN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HOOD

IREN

LMND

MARA

NNOX

RIOT

RXRX

MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday

GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) formed a strategic collaboration with DeepHealth, a RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41874204/ge-healthcare-and-radnet-forge-collaboration-to-transform-imaging-systems-and-accelerate-the-adopt" rel="noreferrer noopener"> to advance AI in imaging</a>.
The companies aim to develop SmartTechnology solutions that leverage AI to improve imaging interpretation, reporting, clinical collaboration, and operational efficiency.
Under the agreement, GE HealthCare will distribute SmartMammo and other DeepHealth solutions to imaging providers across the U.S. as part of its comprehensive imaging technology portfolio.
Beyond SmartMammo, the two companies plan to explore further collaboration on SmartTechnology solutions in other modalities and clinical domains, aiming to broaden access to and enhance the impact of AI-powered workflows.
This collaboration aims to enhance breast cancer screening by integrating AI-driven clinical imaging support to improve detection and diagnosis during the critical early stages of treatment.
The collaboration between GE HealthCare and DeepHealth will also incorporate Smart Alerts, a DeepHealth workflow solution integrated with Senographe Pristina. This feature uses rapid AI processing to quickly identify potentially suspicious lesions, alerting imaging sites within minutes.
The goal is to enable same-day diagnostic exams, improve follow-up compliance, and reduce anxiety for women with potentially concerning findings.
Roland Rott, President &amp; Chief Executive Officer of Imaging for GE HealthCare stated, &#8220;As we look to make more personalized, patient-centered breast care a reality – AI continues to show great promise in breast cancer screening from early detection and risk prediction, to reduced callbacks and more efficient workflows for breast imaging providers.&#8221;
Investors can gain exposure to the stock via Spinnaker ETF Series Langar Global HealthTech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGHT#NYSE">LGHT</a>) and Invesco S&amp;P Spin-Off ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSD#NYSE">CSD</a>).
Price Action: GEHC shares are up 0.31% at $86.21 premarket at the last check Monday.
Image by PDPics from Pixabay
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41455053/ge-vernova-vs-ge-healthcare-betting-on-power-or-medical-tech-to-lead-ai-powered-fut" target="_blank" rel="noreferrer noopener">GE Vernova Vs. GE Healthcare: Betting On Power Or Medical Tech To Lead AI-Powered Future?</a></li>
</ul>

Equities

Large Cap

Health Care

Contracts

General

GEHC

LGHT

GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details

RadNet shares are trading higher after the company reported better-than-expected Q3 financial results.

On Sunday, RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) reported revenue of $461.1 million for the third quarter of 2024, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41869617/radnet-reports-third-quarter-financial-results-with-record-quarterly-revenue-and-adjusted-ebitda-a" rel="noreferrer noopener">consensus of $437.88 million</a>.
Revenue from the Digital Health reportable segment increased 34.3% to $16.4 million, partly due to a $2.2 million increase in AI Revenue, which climbed to $5.1 million during the third quarter. The increase was mainly due to the continuing success of the rollout of the Enhanced Breast Cancer Detection DeepHealth AI-powered screening mammography program.
Aggregate procedural volumes in the third quarter of 2024 increased 9%, and same-center procedural volumes increased 5.5% compared with the third quarter of 2023.
Howard Berger, President and CEO of RadNet, commented, &#8220;We continue to demonstrate strong growth and record results in each of our Imaging Center and Digital Health reportable operating segments.&#8221;
The outpatient imaging centers network reported an adjusted EBITDA&nbsp;of $73.7 million, an increase of 27.2%.
&#8220;Despite continued inflation in staffing costs, improved reimbursement from commercial and capitated payors, strong demand for advanced imaging modalities, the growth of the Digital Health businesses and effective cost controls resulted in an increase to Adjusted EBITDA&nbsp;margins,&#8221; Berger added.
The company reported adjusted EPS of $0.18, up from $0.13 a year ago and beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.15</a>.
Guidance: RadNet raised its previously announced guidance levels.
The company expects Imaging Center Segment 2024 sales of $1.71 billion—$1.76 billion, up from prior guidance of $1.685 billion—$1.735 billion.
The company maintains its 2024 revenue guidance for the Digital Health Segment at $60 million—$70 million.
&#8220;Given the positive trends we continue to experience in virtually all aspects of our business and the strong financial performance of the third quarter, we are revising upwards certain guidance levels in anticipation of financial results that we believe will exceed both our original expectations and the adjustments we made to the guidance ranges upon releasing our first and second quarter 2024 results,&#8221; added Berger.
Furthermore, the company adds that it has 15 centers in various stages of construction and development that it intends to open in 2025.
Price Action: At last check on Monday, RDNT stock was up 17.20% at $85 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41866389/biontech-earns-upgrade-from-goldman-sachs-as-investment-thesis-shifts-toward-cancer-potential" target="_blank" rel="noreferrer noopener">BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential</a></li>
</ul>

Earnings

Guidance

Imaging Centers Operator RadNet Q3 Earnings: Strong Q3 Performance On Positive Trends, Raises Annual Outlook

<ul>
<li>Collaboration will leverage GE HealthCare's legacy and scale of imaging innovation and RadNet's DeepHealth AI-powered clinical and workflow solutions to further the innovation, commercialization, and adoption of AI in imaging.</li>
<li>Together, GE HealthCare and RadNet's DeepHealth aim to create SmartTechnology&#x2122; solutions that harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain to improve speed, clinical accuracy, operational efficiency, and elevate patient care.</li>
<li>To demonstrate the promise of this strategic relationship, the collaboration will first work to bring together DeepHealth's AI-powered SmartMammo&#x2122; 1 solution with GE HealthCare's patient-centric Senographe Pristina&#x2122; mammography system to enhance the way women receive breast care.</li>
<li>The two companies intend to explore additional areas of collaboration to further expand the access and impact of AI-based workflows in other imaging modalities.</li>
</ul>

GE Healthcare And RadNet's Subsidiary DeepHealth, To Collaborate For AI In Imaging, The Companies Aim To Develop SmartTechnology Solutions

RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.15 by 20 percent. This is a 38.46 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $461.142 million which beat the analyst consensus estimate of $437.879 million by 5.31 percent. This is a 14.72 percent increase over sales of $401.968 million the same period last year.

Earnings Beats

RadNet Q3 2024 Adj. EPS $0.18 Beats $0.15 Estimate, Sales $461.142M Beat $437.879M Estimate

By utilizing the cloud-native and modular capabilities of DeepHealth OS, ONRAD will implement a customized solutions roadmap targeted to streamline its clinical and operational workflows, enhancing productivity, and ultimately improving patient outcomes through AI-powered, unified data integration.

RadNet Announced That ONRAD Has Selected RadNet's DeepHealth OS To Advance Its Next Generation Of Radiology Services

DeepHealth, a wholly-owned subsidiary of RadNet (RDNT), has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMa...

RadNet's DeepHealth expands FDA clearance for SmartMammo solutionGE

Truist Financial analyst David S Macdonald reiterated a Buy rating on Radnet (RDNT – Research Report) today and set a price target of $94.00. The c...

Truist Financial Sticks to Their Buy Rating for Radnet (RDNT)

Truist raised the firm's price target on RadNet (RDNT) to $94 from $80 and keeps a Buy rating on the shares. The firm, which is updating its estima...

RadNet price target raised to $94 from $80 at Truist

DeepHealth, a wholly-owned subsidiary of RadNet (RDNT), has received expanded FDA 510(k) clearance for its mammography software. SmartMammo Dx, the...

RadNet's DeepHealth expands FDA clearance for SmartMammo solution

DeepHealth has launched new AI-powered solutions at RSNA 2024. These solutions enable breakthroughs in imaging-based diagnosis, population health s...

RadNet's DeepHealth launches new AI-powered solutions at RSNA 2024

Barclays raised the firm's price target on RadNet (RDNT) to $85 from $79 and keeps an Overweight rating on the shares. The firm walked away from th...

RadNet price target raised to $85 from $79 at Barclays

Barclays analyst Andrew Mok CFA maintained a Buy rating on Radnet (RDNT – Research Report) yesterday and set a price target of $74.00. The company'...

Barclays Keeps Their Buy Rating on Radnet (RDNT)

Barclays lowered the firm's price target on RadNet (RDNT) to $74 from $85 and keeps an Overweight rating on the shares. Against a backdrop of post-...

RadNet price target lowered to $74 from $85 at Barclays

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Radnet (RDNT – Research Report), Century Therapeutic...

Analysts' Top Healthcare Picks: Radnet (RDNT), Century Therapeutics (IPSC)

Baron Health Care Fund Q4 2024 Shareholder Letter

ACLX

ARGNF

ARGX

AZNCF

BCAP

BROE

EOLS

EWTX

GKOS

IPSC

ISRG

NTRA

REGN

VRTX

Press Releases

RadNet Secures Commitments to Amend its Credit Facility, Resulting in 0.25% Reduction in Interest Rates

RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution

CORRECTION: RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution

RadNet's Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety

Maverick Medical AI Announces Completion of The Implementation of Its Real-Time Autonomous Medical Coding Solution at RadNet

Siemens Healthineers and RadNet's Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™

RadNet's Wholly-Owned Subsidiary, DeepHealth, Launches New AI-powered Informatics and SmartTechnology™ Innovations at #RSNA2024

RadNet, Inc. to Present at the BofA Securities 2024 Leveraged Finance Conference on December 3, 2024

Ketryx Announces DeepHealth Selected Its Software to Accelerate AI-Powered Health Informatics Innovation

RadNet, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference January 15th, 2025

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

RadNet

空売り

RadNet (NASDAQ:RDNT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル